NCT05283083: DECATSepsis

Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality

Completed Phase 2 Last updated 6 May 2023

What this trial tests

Phase 2 trial testing Dexmedetomidine in Septic Shock in 90 participants. Completed in 1 March 2023.

Timeline

25 March 2022

Primary endpoint
1 February 2023

1 March 2023

Quick facts

Lead sponsor	Mansoura University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	25 March 2022
Primary completion	1 February 2023
Estimated completion	1 March 2023
Sites	1 location across Egypt

Drugs / interventions tested

• Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

• Septic Shock — all drugs for Septic Shock →
• Sepsis — all drugs for Sepsis →

Sponsor

Mansoura University

Who can join

18 and older, any sex, with Septic Shock or Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to determine whether the infusion of DEX in septic shock can reduce in-hospital mortality, norepinephrine infusion, need and duration for mechanical ventilation, and acute kidney injury without significant adverse events.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Dexmedetomidine for Reducing Mortality in Patients With Septic Shock: A Randomized Controlled Trial (DecatSepsis).
   Ezz Al-Regal AR, Ramzy EA, Atia AAA, Emara MM. · · 2024 · cited 12× · PMID 39004217 · DOI 10.1016/j.chest.2024.06.3794
2. Dexmedetomidine for Reduction of Mortality in Septic Shock: a Protocol for a Randomized Controlled Trial (DecatSepsis)
   Al-regal ARE, Ramzy EA, Atia AAA, Emara MM. · · 2023 · DOI 10.21203/rs.3.rs-2891443/v1